Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 12 Issue 2, May 2018

Volume 12 Issue 2

Medtech Dealmakers

An annual review of the dealmaking and financial trends

Cover image: Scientific research concept. ClaudioVentrella, Thinkstock.

Annual review of the dealmaking and financial trends

    Feature

  • News Feature |

    Although dealmaking in the medtech industry slowed in 2017, political developments and innovations in areas such as digital health technologies could fuel greater activity in 2018.

    • Amanda Micklus
    • Maureen Riordan
  • Profiles

  • Advertisement Feature |

    Targeting a largely unmet and potentially billion-dollar market, SnooZeal is developing a clinically proven daytime treatment for snoring and sleep apnea.

    • SnooZeal
  • Advertisement Feature |

    With its innovative bone graft scaffold, GreenBone Ortho srl is well on its way to becoming a worldwide leader in bone regeneration.

    • GreenBone Ortho srl
  • Advertisement Feature |

    Pacific Edge’s state-of-the-art suite of bladder cancer detection and management tests are noninvasive, highly effective, and more accurate than other urine-based cancer diagnostic tests, and are now being adopted into the standard of care.

    • Pacific Edge Ltd
  • Advertisement Feature |

    Andarix Pharmaceuticals is a clinical-stage company that develops highly specific radiolabeled peptides for targeted radiotherapy and diagnostic imaging in cancer.

    • Andarix
  • Advertisement Feature |

    Arquer Diagnostics is developing a series of innovative, non-invasive tests for cancer and recently launched ADXBLADDER, a reliable urine test for bladder cancer.

    • Arquer Diagnostics
  • Advertisement Feature |

    Karius has developed a cell-free-DNA-based diagnostic test capable of identifying bacteria, mycobacteria, DNA viruses, fungi and protozoa in the blood down to the species level, thereby rapidly improving the diagnosis of infectious diseases.

    • Karius Inc.

Search

Quick links